{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:35:35Z","timestamp":1791311735248,"version":"4.3.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/rlu.0000000000000666","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T14:06:46Z","timestamp":1419948406000},"page":"e111-e116","source":"Crossref","is-referenced-by-count":22,"title":["18F-FDG and 18F-Florbetapir PET in Clinical Practice"],"prefix":"10.1097","volume":"40","author":[{"given":"Matthieu","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Joao Santiago","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johny","family":"Vercouillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hommet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Guilloteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210204","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimers disease with Pittsburgh compound-B.","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"R2-30-20210204","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia.","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"R3-30-20210204","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","article-title":"Voxel-based analysis of PET amyloid ligand 11CPIB uptake in Alzheimer disease.","volume":"67","author":"Kemppainen","year":"2006","journal-title":"Neurology"},{"key":"R4-30-20210204","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/brain\/awm238","article-title":"Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimers disease.","volume":"130","author":"Pike","year":"2007","journal-title":"Brain"},{"key":"R5-30-20210204","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"11CPIB in a nondemented population: potential antecedent marker of Alzheimer disease.","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"R7-30-20210204","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1474-4422(12)70158-8","article-title":"Imaging cerebral amyloid plaques: clinical perspective.","volume":"11","author":"Herholz","year":"2012","journal-title":"Lancet Neurol"},{"key":"R8-30-20210204","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semnuclmed.2011.02.005","article-title":"Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.","volume":"41","author":"Vallabhajosula","year":"2011","journal-title":"Semin Nucl Med"},{"key":"R9-30-20210204","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology.","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"R10-30-20210204","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","article-title":"Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.","volume":"39","author":"Camus","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-30-20210204","first-page":"193","article-title":"La neuro-imagerie au service de la maladie dAlzheimer.","volume":"27","author":"Chetelat","year":"2011","journal-title":"Med Sci"},{"key":"R12-30-20210204","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"R13-30-20210204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"R14-30-20210204","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome.","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"R15-30-20210204","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimers disease: a new lexicon.","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"R16-30-20210204","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria.","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"R17-30-20210204","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R18-30-20210204","first-page":"250","article-title":"FDG- and amyloid-PET in Alzheimers disease: is the whole greater than the sum of the parts Q J Nucl Med Mol Imaging.","volume":"55","author":"Mosconi","year":"2011","journal-title":""},{"key":"R19-30-20210204","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.191044198","article-title":"Prediction of cognitive decline in normal elderly subjects with 2-(18)Ffluoro-2-deoxy-D-glucosepoitron-emission tomography (FDGPET).","volume":"98","author":"de Leon","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-30-20210204","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00259-008-1039-z","article-title":"FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimers disease.","volume":"36","author":"Mosconi","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-30-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410420114","article-title":"Metabolic reduction in the posterior cingulate cortex in very early Alzheimers disease.","volume":"42","author":"Minoshima","year":"1997","journal-title":"Ann Neurol"},{"key":"R22-30-20210204","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.108.058529","article-title":"Comparison of 18F-FDG and PiB PET in cognitive impairment.","volume":"50","author":"Lowe","year":"2009","journal-title":"J Nucl Med"},{"key":"R23-30-20210204","first-page":"309","article-title":"Diffuse senile plaques occur commonly in the cerebellum in Alzheimers disease.","volume":"135","author":"Joachim","year":"1989","journal-title":"Am J Pathol"},{"key":"R24-30-20210204","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1523\/JNEUROSCI.23-06-02086.2003","article-title":"The binding of 2-(4-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.","volume":"23","author":"Klunk","year":"2003","journal-title":"J Neurosci"},{"key":"R25-30-20210204","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archneur.1983.04050110029003","article-title":"The fluorodeoxyglucose 18F scan in Alzheimers disease and multi-infarct dementia.","volume":"40","author":"Benson","year":"1983","journal-title":"Arch Neurol"},{"key":"R26-30-20210204","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0197-4580(01)00230-5","article-title":"Hippocampal formation glucose metabolism and volume losses in MCI and AD.","volume":"22","author":"De Santi","year":"2001","journal-title":"Neurobiol Aging"},{"key":"R27-30-20210204","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/01.WNL.0000163856.13524.08","article-title":"Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.","volume":"64","author":"Mosconi","year":"2005","journal-title":"Neurology"},{"key":"R28-30-20210204","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1046\/j.1460-9568.2003.02999.x","article-title":"Retrosplenial cortex (BA 2930) hypometabolism in mild cognitive impairment (prodromal Alzheimers disease).","volume":"18","author":"Nestor","year":"2003","journal-title":"Eur J Neurosci"},{"key":"R29-30-20210204","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00259-003-1194-1","article-title":"Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimers disease: a PET follow-up study.","volume":"30","author":"Drzezga","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R30-30-20210204","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(94)92871-1","article-title":"Posterior cingulate cortex in Alzheimers disease.","volume":"344","author":"Minoshima","year":"1994","journal-title":"Lancet"},{"key":"R31-30-20210204","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-008-0833-y","article-title":"Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimers disease.","volume":"35","author":"Li","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R32-30-20210204","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","article-title":"Amyloid, hypometabolism, and cognition in Alzheimer disease: an 11CPIB and 18FFDG PET study.","volume":"68","author":"Edison","year":"2007","journal-title":"Neurology"},{"key":"R33-30-20210204","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study.","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"R34-30-20210204","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","article-title":"PET imaging of amyloid deposition in patients with mild cognitive impairment.","volume":"29","author":"Forsberg","year":"2008","journal-title":"Neurobiol Aging"},{"key":"R35-30-20210204","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/brain\/awr044","article-title":"Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.","volume":"134","author":"Tosun","year":"2011","journal-title":"Brain"},{"key":"R36-30-20210204","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment.","volume":"355","author":"Small","year":"2006","journal-title":"N Engl J Med"},{"key":"R37-30-20210204","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","article-title":"Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.","volume":"68","author":"Fleisher","year":"2011","journal-title":"Arch Neurol"},{"key":"R38-30-20210204","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir corrected F 18).","volume":"51","author":"Wong","year":"2010","journal-title":"J Nucl Med"},{"key":"R39-30-20210204","doi-asserted-by":"crossref","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","article-title":"Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimers disease dementia.","volume":"32","author":"La Joie","year":"2012","journal-title":"J Neurosci"},{"key":"R40-30-20210204","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","article-title":"Amyloid imaging in Alzheimers disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.","volume":"83","author":"Wolk","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R41-30-20210204","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","article-title":"Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences.","volume":"78","author":"Rodrigue","year":"2012","journal-title":"Neurology"},{"key":"R42-30-20210204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2191-219X-3-43","article-title":"Cortical florbetapir-PET amyloid load in prodromal Alzheimers disease patients.","volume":"3","author":"Saint-Aubert","year":"2013","journal-title":"EJNMMI Res"},{"key":"R43-30-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid--specific PET radioligand.","volume":"53","author":"Cselenyi","year":"2012","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:10:39Z","timestamp":1620972639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201502000-00030"}},"subtitle":["Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease"],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000666","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}